Skip to main content
. Author manuscript; available in PMC: 2019 Mar 28.
Published in final edited form as: J Control Release. 2018 Jan 31;274:69–80. doi: 10.1016/j.jconrel.2018.01.020

Figure 3. atRA-ePTFE and atRA-POC-ePTFE exhibit sustained release of atRA for 30 days and are biocompatible in vitro.

Figure 3

(A) Representative high performance chromatography (HPLC) performed on samples of retinoic acid (RA, standard), and releasate from atRA-ePTFE and atRA-POC-ePTFE. (B–D) Quantification of the isoforms of RA released from ePTFE, POC-ePTFE, atRA-ePTFE, and atRA-POC-ePTFE grafts including: (B) atRA, (C) 9-cis RA, and (D) 13-cis RA over 32 days. (E) Assessment of the percent complement activation elicited by POC-ePTFE, atRA-ePTFE, atRA-POC-ePTFE grafts as compared with ePTFE alone. (F) Assessment of the percent platelet aggregation elicited by POC-ePTFE, atRA-ePTFE, and atRA-POC-ePTFE as compared with ePTFE alone. ADP (100 μM). Data represent the mean ± SE (n=3), analysis via one-way ANOVA. ePTFE: extended polytetrafluroethylene, POC-ePTFE: poly(1,8 octamethylene citrate) ePTFE, atRA-ePTFE: all-trans retinoic acid-coated ePTFE, and atRA-POC-ePTFE: all-trans retinoic acid- poly(1,8 octamethylene citrate) ePTFE